pentobarbital will minimize the level or impact of diazepam buccal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe. Powerful or reasonable CYP3A4 inducers may well increase price of diazepam elimination; for that reason, efficacy of diazepam can be lessened.
buprenorphine subdermal implant and pentobarbital the two maximize sedation. Stay clear of or Use Alternate Drug. Restrict use to sufferers for whom alternate procedure solutions are inadequate
pentobarbital will reduce the extent or result of atogepant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Proposed atogepant dosage with concomitant usage of powerful or reasonable CYP3A4 inducers is 30 mg or sixty mg qDay.
pentobarbital will lessen the extent or effect of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay clear of coadministration. Solid or reasonable CYP3A inducers may well minimize cobimetinib systemic publicity by >eighty% and reduce its efficacy.
pentobarbital will lower the extent or effect of saxagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Mysterious.
pentobarbital will decrease the level or effect of ketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Mysterious.
Barbiturates can induce hepatic microsomal enzymes leading to enhanced metabolism and lowered anticoagulant reaction of oral anticoagulants (eg, warfarin, acenocoumarol, dicumarol, and phenprocoumon); patients stabilized on anticoagulant therapy may well need dosage changes if barbiturates are extra to or withdrawn from their dosage regimen
pentobarbital will reduce the extent or influence of fosamprenavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will minimize the extent or outcome of etoposide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will lower the extent or impact of Nembutal zonisamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Not known.
Soon after stopping a CYP3A4 inducer, as the effects from the inducer decrease, the fentanyl plasma concentration will increase which could enhance or extend both the therapeutic and adverse effects.
pentobarbital boosts results of ifosfamide by influencing hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Coadministration of ifosfamide with CYP2B6 inducers may possibly maximize metabolism of ifosfamide to its metabolite. Check for greater results/toxicities if coupled with CYP2B6 inducers.
Barbiturates may cause fetal damage when administered to a pregnant girl; retrospective, scenario-managed studies have recommended a connection amongst maternal consumption of barbiturates and a higher-than-predicted incidence of fetal abnormalities
pentobarbital will lessen the level or outcome of alfuzosin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.